通过微RNA传递解开表观遗传调制:阿尔茨海默病的治疗前沿
Shivangi Paliwal1, Jayant Singh Bhardwaj1, Chih Hao Yang2
1Department of Pharmacy, Birla Institute of Technology and Sciences, Pilani, 333031, Rajasthan, India.
Molecular neurobiology
|March 17, 2026
概括
这项研究探讨了microRNAs (miRNAs) 如何影响阿尔茨海默病 (AD) 途径,并建议基于miRNA的治疗方法. 了解miRNA基因调节为AD提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 涉及破坏的Wnt/β-catenin和PI3K/Akt信号通路.
- 这些干扰影响神经发生,神经元存活,神经炎症和血脑屏障的完整性.
- 表观遗传调节者,特别是微RNA (miRNA),影响了AD中的这些途径.
研究的目的:
- 研究PI3K-Akt和Wnt/β-catenin通路在AD中的作用.
- 评估表观遗传调节剂,特别是miRNAs,作为AD的潜在治疗点.
- 检查miRNA对Aβ积累,病理和神经炎症的影响.
主要方法:
- 文献综述侧重于miRNA参与阿尔茨海默氏病变的发生.
- 对miRNA对关键AD特征的影响分析:粉样β (Aβ) 和tau病理学.
- 探索用于治疗应用的外体介导miRNA输送.
主要成果:
- miRNAs显著调节影响AD进展的基因表达.
- miRNAs与Aβ积累,高酸化和神经炎症有关.
- 外基因组显示出在阿尔茨海默病治疗中具有向miRNA传递的潜力.
结论:
- miRNAs是阿尔茨海默氏症疾病途径的关键调节者.
- 基于miRNA的治疗方法 (模仿剂/抑制剂) 对阿尔茨海默症治疗具有前景.
- 对miRNA基因调节和传递系统的进一步研究对于推进AD疗法至关重要.
相关概念视频
MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs
24.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K
MicroRNAs
12.0K
12.0K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
siRNA - Small Interfering RNAs
19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K


